reglab/housing_qa huggingface dataset:
UT Code § 26-53-301 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 53 - Protection of Athletes with Head Injuries Act|Part 3 - Medical Clearance|Section 301 - Removal of child suspected of sustaining concussion or a traumatic head injury -- Medical clearance required before return to participation.

26-53-301. Removal of child suspected of sustaining concussion or a traumatic head injury -- Medical clearance required before return to participation.    (1) An amateur sports organization, and each agent of the amateur sports organization, shall:   (a) immediately remove a child from participating in a sporting event of the amateur sports organization if the child is suspected of sustaining a concussion or a traumatic head injury; and     (b) prohibit the child described in Subsection (1)(a) from participating in a sporting event of the amateur sports organization until the child:   (i) is evaluated by a qualified health care provider who is trained in the evaluation and management of a concussion; and     (ii) provides the amateur sports organization with a written statement from the qualified health care provider described in Subsection (1)(b)(i) stating that:   (A) the qualified health care provider has, within three years before the day on which the written statement is made, successfully completed a continuing education course in the evaluation and management of a concussion; and     (B) the child is cleared to resume participation in the sporting event of the amateur sports organization.           (2) This section does not create a new cause of action.    Enacted by Chapter 97, 2011 General Session
UT Code § 26-53-401 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 53 - Protection of Athletes with Head Injuries Act|Part 4 - Student Injury Evaluation|Section 401 - School nurses evaluating student injuries.

 Effective 5/13/2014  26-53-401. School nurses evaluating student injuries.    (1) A school nurse may assess a child who is suspected of sustaining a concussion or a traumatic head injury during school hours on school property regardless of whether the nurse has received specialized training in the evaluation and management of a concussion.     (2) A school nurse who does not meet the requirements of Subsections 26-53-301(1)(b)(i) and (1)(b)(ii)(A), but who assesses a child who is suspected of sustaining a concussion or traumatic head injury under Subsection (1):   (a) shall refer the child to a qualified health care provider who is trained in the evaluation and management of a concussion; and     (b) may not provide a written statement permitting the child to resume participation in free play or physical education class under Subsection 26-53-301(1)(b)(ii).       (3) A school nurse shall undergo training in the evaluation and management of a concussion, as funding allows.    Amended by Chapter 165, 2014 General Session
UT Code § 26-61-101 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61 - Cannabinoid Research Act|Part 1 - General Provisions|Section 101 - Title.

 Effective 3/25/2017  26-61-101. Title.  This chapter is known as "Cannabinoid Research Act." Enacted by Chapter 398, 2017 General Session  Technically renumbered to avoid duplication of section number also enacted in HB345, Chapter 413.
UT Code § 26-61-102 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61 - Cannabinoid Research Act|Part 1 - General Provisions|Section 102 - Definitions.

 Effective 3/25/2017  26-61-102. Definitions.  As used in this chapter:  (1) "Approved study" means a medical research study:   (a) the purpose of which is to investigate the medical benefits and risks of cannabinoid products; and     (b) that is approved by an IRB.       (2) "Board" means the Cannabinoid Product Board created in Section 26-61-201.     (3) "Cannabinoid product" means the same as that term is defined in Section 58-37-3.6.     (4) "Cannabis" means the same as that term is defined in Section 58-37-3.6.     (5) "Expanded cannabinoid product" means the same as that term is defined in Section 58-37-3.6.     (6) "Institutional review board" or "IRB" means an institutional review board that is registered for human subject research by the United States Department of Health and Human Services.    Enacted by Chapter 398, 2017 General Session  Technically renumbered to avoid duplication of section number also enacted in HB345, Chapter 413.
UT Code § 26-61-103 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61 - Cannabinoid Research Act|Part 1 - General Provisions|Section 103 - Institutional review board -- Approved study of cannabis, a cannabinoid product, or an expanded cannabinoid product.

 Effective 3/25/2017  26-61-103. Institutional review board -- Approved study of cannabis, a cannabinoid product, or an expanded cannabinoid product.    (1) A person conducting an approved study may, for the purposes of the study:   (a) process a cannabinoid product or an expanded cannabinoid product;     (b) possess a cannabinoid product or an expanded cannabinoid product; and     (c) administer a cannabinoid product, or an expanded cannabinoid product to an individual in accordance with the approved study.       (2) A person conducting an approved study may:   (a) import cannabis, a cannabinoid product, or an expanded cannabinoid product from another state if:   (i) the importation complies with federal law; and     (ii) the person uses the cannabis, cannabinoid product, or expanded cannabinoid product in accordance with the approved study; or       (b) obtain cannabis, a cannabinoid product, or an expanded cannabinoid product from the National Institute on Drug Abuse.       (3) A person conducting an approved study may distribute cannabis, a cannabinoid product, or an expanded cannabinoid product outside the state if:   (a) the distribution complies with federal law; and     (b) the distribution is for the purposes of, and in accordance with, the approved study.      Enacted by Chapter 398, 2017 General Session  Technically renumbered to avoid duplication of section number also enacted in HB345, Chapter 413.
UT Code § 26-61-201 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61 - Cannabinoid Research Act|Part 2 - Cannabinoid Product Board|Section 201 - Cannabinoid Product Board.

 Effective 5/8/2018  26-61-201. Cannabinoid Product Board.    (1) There is created the Cannabinoid Product Board within the department.     (2) The department shall appoint, in consultation with a professional association based in the state that represents physicians, seven members to the Cannabinoid Product Board as follows:   (a) three individuals who are medical research professionals; and     (b) four physicians.       (3) The department shall ensure that at least one of the board members appointed under Subsection (2) is a member of the Controlled Substances Advisory Committee created in Section 58-38a-201.     (4)   (a) Four of the board members appointed under Subsection (2) shall serve an initial term of two years and three of the board members appointed under Subsection (2) shall serve an initial term of four years.     (b) Successor board members shall each serve a term of four years.       (5) The department may remove a board member without cause.     (6) The board shall nominate a board member to serve as chairperson of the board by a majority vote of the board members.     (7) The board shall meet as often as necessary to accomplish the duties assigned to the board under this chapter.     (8) Each board member, including the chair, has one vote.     (9)   (a) A majority of board members constitutes a quorum.     (b) A vote of a majority of the quorum at any board meeting is necessary to take action on behalf of the board.       (10) A board member may not receive compensation for the member's service on the board, but may, in accordance with rules adopted by the board in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, receive:   (a) per diem at the rate established under Section 63A-3-106; and     (b) travel expenses at the rate established under Section 63A-3-107.      Amended by Chapter 110, 2018 General Session
UT Code § 26-61-202 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61 - Cannabinoid Research Act|Part 2 - Cannabinoid Product Board|Section 202 - Cannabinoid Product Board -- Duties.

 Effective 1/1/2022  26-61-202. Cannabinoid Product Board -- Duties.    (1) The board shall review any available scientific research related to the human use of cannabis, a cannabinoid product, or an expanded cannabinoid product that:   (a) was conducted under a study approved by an IRB;     (b) was conducted or approved by the federal government; or     (c)   (i) was conducted in another country; and     (ii) demonstrates, as determined by the board, a sufficient level of scientific reliability and significance to merit the board's review.         (2) Based on the research described in Subsection (1), the board shall evaluate the safety and efficacy of cannabis, cannabinoid products, and expanded cannabinoid products, including:   (a) medical conditions that respond to cannabis, cannabinoid products, and expanded cannabinoid products;     (b) cannabis and cannabinoid dosage amounts and medical dosage forms;     (c) interaction of cannabis, cannabinoid products, and expanded cannabinoid products with other treatments; and     (d) contraindications, adverse reactions, and potential side effects from use of cannabis, cannabinoid products, and expanded cannabinoid products.       (3) Based on the board's evaluation under Subsection (2), the board shall develop guidelines for treatment with cannabis, a cannabinoid product, and an expanded cannabinoid product that include:   (a) a list of medical conditions, if any, that the board determines are appropriate for treatment with cannabis, a cannabis product, a cannabinoid product, or an expanded cannabinoid product;     (b) a list of contraindications, side effects, and adverse reactions that are associated with use of cannabis, cannabinoid products, or expanded cannabinoid products;     (c) a list of potential drug-drug interactions between medications that the United States Food and Drug Administration has approved and cannabis, cannabinoid products, and expanded cannabinoid products; and     (d) any other guideline the board determines appropriate.       (4) The board shall submit the guidelines described in Subsection (3) to the director of the Division of Occupational and Professional Licensing.     (5) Guidelines that the board develops under this section may not limit the availability of cannabis, cannabinoid products, or expanded cannabinoid products permitted under Title 4, Chapter 41a, Cannabis Production Establishments, or Title 26, Chapter 61a, Utah Medical Cannabis Act.    Amended by Chapter 12, 2020 General Session
UT Code § 26-61a-101 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61a - Utah Medical Cannabis Act|Part 1 - General Provisions|Section 101 - Title.

 Effective 12/3/2018  26-61a-101. Title.  This chapter is known as "Utah Medical Cannabis Act." Renumbered and Amended by Chapter 1, 2018 Special Session 3
UT Code § 26-61a-108 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61a - Utah Medical Cannabis Act|Part 1 - General Provisions|Section 108 - Agreement with a tribe.

 Effective 12/3/2018  26-61a-108. Agreement with a tribe.    (1) As used in this section, "tribe" means a federally recognized Indian tribe or Indian band.     (2)   (a) In accordance with this section, the governor may enter into an agreement with a tribe to allow for the operation of a medical cannabis pharmacy on tribal land located within the state.     (b) An agreement described in Subsection (2)(a) may not exempt any person from the requirements of this chapter.     (c) The governor shall ensure that an agreement described in Subsection (2)(a):   (i) is in writing;     (ii) is signed by:   (A) the governor; and     (B) the governing body of the tribe that the tribe designates and has the authority to bind the tribe to the terms of the agreement;       (iii) states the effective date of the agreement;     (iv) provides that the governor shall renegotiate the agreement if the agreement is or becomes inconsistent with a state statute; and     (v) includes any accommodation that the tribe makes:   (A) to which the tribe agrees; and     (B) that is reasonably related to the agreement.         (d) Before executing an agreement under this Subsection (2), the governor shall consult with the department.     (e) At least 30 days before the execution of an agreement described in this Subsection (2), the governor or the governor's designee shall provide a copy of the agreement in the form in which the agreement will be executed to:   (i) the chairs of the Native American Legislative Liaison Committee; and     (ii) the Office of Legislative Research and General Counsel.        Enacted by Chapter 1, 2018 Special Session 3
UT Code § 26-61a-109 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61a - Utah Medical Cannabis Act|Part 1 - General Provisions|Section 109 - Qualified Patient Enterprise Fund -- Creation -- Revenue neutrality.

 Effective 9/23/2019  26-61a-109. Qualified Patient Enterprise Fund -- Creation -- Revenue neutrality.    (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund."     (2) The fund created in this section is funded from:   (a) money the department deposits into the fund under this chapter;     (b) appropriations the Legislature makes to the fund; and     (c) the interest described in Subsection (3).       (3) Interest earned on the fund shall be deposited into the fund.     (4) The department may only use money in the fund to fund the department's responsibilities under this chapter.     (5) The department shall set fees authorized under this chapter in amounts that the department anticipates are necessary, in total, to cover the department's cost to implement this chapter.    Amended by Chapter 5, 2019 Special Session 1
UT Code § 26-61a-112 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61a - Utah Medical Cannabis Act|Part 1 - General Provisions|Section 112 - No insurance requirement.

 Effective 12/3/2018  26-61a-112. No insurance requirement.  Nothing in this chapter requires an insurer, a third-party administrator, or an employer to pay or reimburse for cannabis, a cannabis product, or a medical cannabis device. Enacted by Chapter 1, 2018 Special Session 3
UT Code § 26-61a-113 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61a - Utah Medical Cannabis Act|Part 1 - General Provisions|Section 113 - No effect on use of hemp extract -- Cannabidiol -- Approved drugs.

 Effective 5/12/2020  26-61a-113. No effect on use of hemp extract -- Cannabidiol -- Approved drugs.    (1) Nothing in this chapter prohibits an individual from purchasing, selling, possessing, or using a cannabinoid product in accordance with Section 4-41-402.     (2) Nothing in this chapter restricts or otherwise affects the prescription, distribution, or dispensing of a product that the United States Food and Drug Administration has approved.    Amended by Chapter 12, 2020 General SessionAmended by Chapter 354, 2020 General Session
UT Code § 26-61a-114 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61a - Utah Medical Cannabis Act|Part 1 - General Provisions|Section 114 - Severability clause.

 Effective 12/3/2018  26-61a-114. Severability clause.    (1) If any provision of this title or Laws of Utah 2018, Third Special Session, Chapter 1 or the application of any provision of this title or Laws of Utah 2018, Third Special Session, Chapter 1 to any person or circumstance is held invalid by a final decision of a court of competent jurisdiction, the remaining provisions of this title and Laws of Utah 2018, Third Special Session, Chapter 1 remain effective without the invalidated provision or application.     (2) The provisions of this title and Laws of Utah 2018, Third Special Session, Chapter 1 are severable.    Enacted by Chapter 1, 2018 Special Session 3
UT Code § 26-61a-115 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61a - Utah Medical Cannabis Act|Part 1 - General Provisions|Section 115 - Analogous to prescribed controlled substances.

 Effective 9/23/2019  26-61a-115. Analogous to prescribed controlled substances.  When an employee, officer, or agent of the state or a political subdivision makes a finding, determination, or otherwise considers an individual's possession or use of cannabis, a cannabis product, or a medical cannabis device, the employee, officer, or agent may not consider the individual's possession or use any differently than the lawful possession or use of any prescribed controlled substance, if the individual's possession or use complies with:  (1) this chapter;     (2)Title 4, Chapter 41a, Cannabis Production Establishments; or     (3) Subsection 58-37-3.7(2) or (3).    Enacted by Chapter 5, 2019 Special Session 1
UT Code § 26-61a-203 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61a - Utah Medical Cannabis Act|Part 2 - Medical Cannabis Card Registration|Section 203 - Designated caregiver -- Guardian -- Criminal background check.

 Effective 9/23/2019  26-61a-203. Designated caregiver -- Guardian -- Criminal background check.    (1) Except for an applicant reapplying for a medical cannabis card within less than one year after the expiration of the applicant's previous medical cannabis card, each applicant for a medical cannabis guardian card under Section 26-61a-201 or a medical cannabis caregiver card under Section 26-61a-202 shall:   (a) submit to the department, at the time of application:   (i) a fingerprint card in a form acceptable to the Department of Public Safety; and     (ii) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the registration of the applicant's fingerprints in the Federal Bureau of Investigation Next Generation Identification System's Rap Back Service; and       (b) consent to a fingerprint background check by:   (i) the Bureau of Criminal Identification; and     (ii) the Federal Bureau of Investigation.         (2) The Bureau of Criminal Identification shall:   (a) check the fingerprints the applicant submits under Subsection (1)(a) against the applicable state, regional, and national criminal records databases, including the Federal Bureau of Investigation Next Generation Identification System;     (b) report the results of the background check to the department;     (c) maintain a separate file of fingerprints that applicants submit under Subsection (1)(a) for search by future submissions to the local and regional criminal records databases, including latent prints;     (d) request that the fingerprints be retained in the Federal Bureau of Investigation Next Generation Identification System's Rap Back Service for search by future submissions to national criminal records databases, including the Next Generation Identification System and latent prints; and     (e) establish a privacy risk mitigation strategy to ensure that the department only receives notifications for an individual with whom the department maintains an authorizing relationship.       (3) The department shall:   (a) assess an applicant who submits fingerprints under Subsection (1)(a) a fee in an amount that the department sets in accordance with Section 63J-1-504 for the services that the Bureau of Criminal Identification or another authorized agency provides under this section; and     (b) remit the fee described in Subsection (3)(a) to the Bureau of Criminal Identification.      Amended by Chapter 5, 2019 Special Session 1
UT Code § 26-61a-302 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61a - Utah Medical Cannabis Act|Part 3 - Medical Cannabis Pharmacy License|Section 302 - Medical cannabis pharmacy owners and directors -- Criminal background checks.

 Effective 9/23/2019  26-61a-302. Medical cannabis pharmacy owners and directors -- Criminal background checks.    (1) Each applicant to whom the department issues a notice of intent to award a license to operate as a medical cannabis pharmacy shall submit, before the department may award the license, from each individual who has a financial or voting interest of 2% or greater in the applicant or who has the power to direct or cause the management or control of the applicant:   (a) a fingerprint card in a form acceptable to the Department of Public Safety;     (b) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the registration of the individual's fingerprints in the Federal Bureau of Investigation Next Generation Identification System's Rap Back Service; and     (c) consent to a fingerprint background check by:   (i) the Bureau of Criminal Identification; and     (ii) the Federal Bureau of Investigation.         (2) The Bureau of Criminal Identification shall:   (a) check the fingerprints the applicant submits under Subsection (1) against the applicable state, regional, and national criminal records databases, including the Federal Bureau of Investigation Next Generation Identification System;     (b) report the results of the background check to the department;     (c) maintain a separate file of fingerprints that applicants submit under Subsection (1) for search by future submissions to the local and regional criminal records databases, including latent prints;     (d) request that the fingerprints be retained in the Federal Bureau of Investigation Next Generation Identification System's Rap Back Service for search by future submissions to national criminal records databases, including the Next Generation Identification System and latent prints; and     (e) establish a privacy risk mitigation strategy to ensure that the department only receives notifications for an individual with whom the department maintains an authorizing relationship.       (3) The department shall:   (a) assess an individual who submits fingerprints under Subsection (1) a fee in an amount that the department sets in accordance with Section 63J-1-504 for the services that the Bureau of Criminal Identification or another authorized agency provides under this section; and     (b) remit the fee described in Subsection (3)(a) to the Bureau of Criminal Identification.      Amended by Chapter 5, 2019 Special Session 1
UT Code § 26-61a-303 (2021)
2021 Utah Code|Title 26 - Utah Health Code|Chapter 61a - Utah Medical Cannabis Act|Part 3 - Medical Cannabis Pharmacy License|Section 303 - Renewal.

 Effective 7/1/2021  26-61a-303. Renewal.    (1) The department shall renew a license under this part every year if, at the time of renewal:   (a) the licensee meets the requirements of Section 26-61a-301;     (b) the licensee pays the department a license renewal fee in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504; and     (c) if the medical cannabis pharmacy changes the operating plan described in Section 26-61a-304 that the department approved under Subsection 26-61a-301(2)(b)(iv), the department approves the new operating plan.       (2)   (a) If a licensed medical cannabis pharmacy abandons the medical cannabis pharmacy's license, the department shall publish notice of an available license:   (i) in a newspaper of general circulation for the geographic area in which the medical cannabis pharmacy license is available; or     (ii) on the Utah Public Notice Website established in Section 63A-16-601.       (b) The department may establish criteria, in collaboration with the Division of Occupational and Professional Licensing and the Board of Pharmacy and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to identify the medical cannabis pharmacy actions that constitute abandonment of a medical cannabis pharmacy license.      Amended by Chapter 84, 2021 General SessionAmended by Chapter 345, 2021 General Session